Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX 7 COMBINATION PACK versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX 7 COMBINATION PACK versus NILSTAT.
MYCELEX-7 COMBINATION PACK vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible.
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category C
Category C
Antifungal
Antifungal